Ocuphire Pharma, Inc. has a global license agreement with Viatris Inc. to co-develop and commercialize PS for the reversal of mydriasis, presbyopia and low light vision disturbances. Under the terms of this agreement, the two companies agreed to co-develop the product for each of these conditions, with Viatris providing funding for development of these programs. Further, Ocuphire is eligible to receive specified regulatory or net sales milestone payments associated with these indications as well as royalties on commercial sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.72 USD | -0.85% | +1.30% | +8.22% |
18/04 | Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says | MT |
18/04 | UK Regulator to Consider Undertakings for Theramex-Viatris Deal | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
11.72 USD | -0.85% | +1.30% | 14.04B | ||
1.94 USD | -3.48% | +22.40% | 51.47M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.22% | 14.04B | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- VTRS Stock
- News Viatris Inc.
- Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc